Background
Hep C (+) volunteers are needed to participate in a four week research study involving an investigational Hep C Cyclophilin B Inhibitor. This is a new class of oral drug to treat Hepatitis C infection.

Qualifying participants will be up to paid $2,100.

Those who qualify will receive routine medical examinations and lab tests in addition to the monetary compensation.

Inclusion Criteria
1. Chronic infection with Hepatitis C Genotype 1
2. A negative urine drug screen
3. HIV negative
4. In generally good health

For more information please contact Dr. Jacob Lalezari of Quest Clinical Research at (415) 353-0800